Ontology highlight
ABSTRACT:
SUBMITTER: Lee RJ
PROVIDER: S-EPMC3684567 | biostudies-literature | 2013 Jun
REPOSITORIES: biostudies-literature
Lee Richard J RJ Saylor Philip J PJ Michaelson M Dror MD Rothenberg S Michael SM Smas Malgorzata E ME Miyamoto David T DT Gurski Carol A CA Xie Wanling W Maheswaran Shyamala S Haber Daniel A DA Goldin Jonathan G JG Smith Matthew R MR
Clinical cancer research : an official journal of the American Association for Cancer Research 20130403 11
<h4>Background</h4>Cabozantinib is an oral MET/VEGFR2 inhibitor. A recent phase II study of cabozantinib (100 mg daily) showed improved bone scans in subjects with metastatic castration-resistant prostate cancer (mCRPC), but adverse events (AE) caused frequent dose reductions. This study was designed to determine the efficacy and tolerability of cabozantinib at lower starting doses.<h4>Experimental design</h4>An adaptive design was used to determine the lowest active daily dose among 60, 40, and ...[more]